Table 1. Clinical characteristics of the major subtypes of 109 PTCL samples.
| Characteristics | PTCL-NOS | NKT | AITL | ALCL | Total | |
|---|---|---|---|---|---|---|
| ALK+ | ALK− | |||||
| Age > 60 | 20/60 (33.3) | 2/18 (11.1) | 6/11 (54.5) | 0/4 (0.0) | 1/4 (25.0) | 29/109 (26.6) |
| Gender, male | 38/60 (63.3) | 13/18 (72.2) | 9/11 (81.8) | 3/4 (75.0) | 3/4 (75.0) | 75/109 (68.8) |
| B symptoms | 47/58 (81.0) | 16/18 (88.9) | 11/11 (100.0) | 4/4 (100.0) | 2/4 (50.0) | 90/107 (84.1) |
| LDH > normal | 36/58 (62.1) | 10/17 (58.8) | 10/11 (90.9) | 4/4 (100.0) | 2/4 (50.0) | 68/105 (64.8) |
| Ann Arbor stage III/IV | 52/58 (89.7) | 15/16 (93.8) | 11/11 (100.0) | 4/4 (100.0) | 3/4 (75.0) | 80/109 (73.4) |
| ECOG > 1 | 30/58 (51.7) | 4/17 (23.5) | 5/11 (45.5) | 3/4 (75.0) | 1/4 (25.0) | 50/106 (47.2) |
| > 1 extranodal site | 29/57 (50.9) | 11/17 (64.7) | 4/11 (36.4) | 4/4 (100.0) | 2/4 (50.0) | 57/104 (54.8) |
| BM involvement | 16/55 (29.1) | 3/17 (17.6) | 1/11 (9.1) | 1/4 (25.0) | 1/4 (25.0) | 25/101 (24.8) |
| IPI > 2 | 35/57 (61.4) | 10/18 (55.6) | 7/11 (63.6) | 4/4 (100.0) | 3/4 (75.0) | 65/105 (61.9) |
| Treatment with CHOP | 26/60 (43.3) | 3/18 (16.7) | 5/11 (45.5) | 3/4 (75.0) | 1/4 (25.0) | 42/109 (38.5) |
CHOP, cyclophosphamide, vindesine, doxorubicin, prednisone; ECOG, Eastern Cooperative Oncology Group; LDH, lactate dehydrogenase.